The glymphatic system and Amyotrophic lateral sclerosis

Area of Science:

• Neuroscience
• Neuroimmunology
• Sleep Science

Background:

• The glymphatic system and meningeal lymphatics clear brain solutes and toxins.
• TDP-43 and glutamate are key in Amyotrophic Lateral Sclerosis (ALS) pathogenesis.
• Glymphatic flow depends on physiological factors and is active during sleep.

Purpose of the Study:

• To review the glymphatic system's potential impact on ALS.
• To consider preclinical sleep impairment as an ALS risk factor.
• To explore therapeutic strategies for enhancing glymphatic flow in ALS.

Main Methods:

• Literature review of glymphatic system function and its relation to neurodegenerative diseases.
• Analysis of the role of TDP-43 and glutamate in ALS.
• Examination of sleep disturbances in ALS and other neurodegenerative conditions.

Main Results:

• The glymphatic system's role in clearing ALS-relevant proteins (TDP-43) and molecules (glutamate) is highlighted.
• Sleep impairment, a known factor in Alzheimer's and Parkinson's, is also prevalent in ALS.
• Preclinical sleep disturbances may represent an unrecognized risk factor for ALS development.

Conclusions:

• The glymphatic system's dysfunction, potentially driven by sleep impairment, warrants investigation as a significant factor in ALS.
• Targeting glymphatic function and improving sleep may offer novel therapeutic avenues for ALS.
• Further research is needed to elucidate the preclinical glymphatic system's role in ALS pathogenesis.